Developments in cancer vaccination

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 716-721

  Lysaght, Joanne ^a   Todryk, Stephen ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antitumor immunity; Cancer vaccines; T cells; Trials; Tumor antigens

Indexed keywords

BCG VACCINE; CANCER VACCINE; DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; PEPTIDE; TUMOR ANTIGEN;

ADVANCED CANCER; CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; REVIEW; SIDE EFFECT; VACCINATION;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS; HUMANS; NEOPLASMS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0041664886     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Pardoll DM: Cancer vaccines. Nat Med (1998) 4(5 Suppl):525-531. A definitive review of cancer vaccines covering the background to tumor immunology.
2. Jager E, Jager D, Knuth A: Clinical cancer vaccine trials. Curr Opin Immunol (2002) 14(2):178-182. An excellent update of clinical trials of cancer vaccines.
3. Schmitz M, Bornhauser M, Ockert D, Rieber EP: Cancer immunotherapy: Novel strategies and clinical experiences. Trends Immunol (2002) 23(9):428-429.
4. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T: Tumor-specific shared antigenic peptides recognized by human T-cells. Immunol Rev (2002) 188(1):51-64.
5. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immuno-therapy. Nat Immunol (2001) 2(4):293-299. Recommended reading for the current concepts of tumor immunology and therapy, including novel approaches.
6. Pawelec G: Tumor escape from the immune response: The last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother (1999) 48(7):343-345.
7. Egen JG, Kuhns MS, Allison JP: CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 3(7):611-618.
8. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Riekenberg J, Chen YT, Ritter G, Hoffman E et al: Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA (2000) 97(22):12198-12203.
9. Gong J, Chen D, Kashiwaba M, Kufe D: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med (1997) 3(5):558-561.
10. Ward S, Casey D, Labarthe M-C, Whelan M, Dalgleish A, Pandha H, Todryk S: Immunotherapeutic potential of whole tumor cells. Cancer Immunol Immunother (2002) 51(7):351-357.
11. Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG et al: Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res (1999) 59(20):5160-5168. A key human study on the use of whole tumor cell vaccines transfected with a cytokine, demonstrating the generation of immune responses.
12. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg (1992) 216(4):463-482.
13. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, Goemann M, Coleman J, Grochow L, Donehower RC, Lillemoe KD et al: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation. J Clin Oncol (2001) 19(1):145-156.
14. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL: Heat shock proteins come of age: Primitive functions acquire new roles in an adaptive world. Immunity (1998) 8(6):657-665. A broad review describing the potential of Hsps as cancer vaccines and their proposed mechanism of action.
15. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4(3):328-332. A key early study involving the in vitro culturing of patient's dendritic cells, which were then 'fed' with tumor antigens and re-administered as a vaccine, demonstrating immune responses and a level of clinical efficacy.
16. Smith SG, Patel PM, Porte J, Selby PJ, Jackson AM: Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Clin Cancer Res (2001) 7(12):4253-4261.
17. Palmowski MJ, Choi EM, Hermans IF, Gilbert SC, Chen JL, Gileadi U, Salio M, Van Pel A, Man S, Bonin E, Liljestron P et al: Competition between CTL narrows the immune response induced by prime-boost vaccination protocols. J Immunol (2002) 168(9):4391-4398. State-of-the-art approach to vaccination, using combinations of viral vectors encoding tumor antigens, and immune monitoring using MHC class I-peptide tetramers. A 'humanized' murine model.
18. Van Der Burg SH, Menon AG, Redeker A, Bonnet MC, Drijfhout JW, Tollenaar RA, Van De Velde CJ, Moingeon P, Kuppen PJ, Offringa R, Melief CJ: Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res (2002) 8(5):1019-1027. Trial of a state-of-the-art approach to vaccination, using a viral vector encoding tumor antigen, and immune monitoring using ELISPOT.
19. Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA: Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol (2001) 19(6)1848-1854. Highlights the important principles for vaccination trials, in particular the different criteria from drug trials.
20. Hsueh EC, Essner R, Foshag LJ, Ollila DW, Gammon G, O'Day SJ, Boasberg PD, Stern SL, Ye X, Morton DL: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 20(23):4549-4554.
21. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF: IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients. J Invest Dermatol (1999) 112(2):205-209.
22. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I et al: Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer (2001) 92(3):441-450.
23. Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli MR, Gallino G, Piris A, Cattelan A, Lazzari I, Carrabba M et al: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. J Clin Oncol (2002) 20(20):4169-4180. One of the first reported trials using Hsp as a cancer vaccine, demonstrating immune responses and a level of clinical efficacy.
24. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG: Toxicity, immunogenicity, and induction of E75-specific tumorlytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res (2002) 8(11):3407-3418.
25. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC, Romero P: CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol (2002) 168(3):1212-1218.
26. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML: Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial. Cancer Res (2000) 60(4):829-833.
27. Gulley J, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg SM, Tsang K, Panicali D, Poole D, Schlom J, Hamilton JM: Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 53(2):109-117.
28. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M, Onon TS, Bauknecht T, Wagner U, Kroon K et al: Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res (2002) 8(12):3676-3685.
29. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest (2002) 109(3):409-417.
30. Pecher G, Haring A, Kaiser L, Thiel E: Mucin gene (MUC1) transfected dendritic cells as vaccine: Results of a phase I/II clinical trial. Cancer Immunol Immunother (2002) 51(11-12):669-673.